Lindsey Harris, MD
Retina Specialist · Houston, TXNPI 1093729402
Payments from drug & device makers
Across 336 payments — averaging $1763.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$458K
- Apellis Pharmaceuticals, Inc.$103K
- Eyepoint US, Inc.$8K
- AbbVie$7K
- Genentech, Inc.$6K
- Janssen Research & Development, LLC$6K
- plus $4K from 24 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 74 | $457,717 |
| Apellis Pharmaceuticals, Inc. | 28 | $103,266 |
| Eyepoint US, Inc. | 3 | $7,822 |
| AbbVie(2 entities) | 12 | $7,005 |
| Genentech, Inc. | 2 | $6,400 |
| Janssen Research & Development, LLC | 1 | $6,000 |
| Regeneron Healthcare Solutions, Inc. | 54 | $1,016 |
| Genentech USA, Inc. | 55 | $758 |
| Sun Pharmaceutical Industries Inc. | 32 | $527 |
| Bausch & Lomb Americas Inc. | 10 | $301 |
| Oyster Point Pharma, Inc. | 9 | $259 |
| Tarsus Pharmaceuticals, Inc. | 5 | $238 |
| Astellas Pharma US Inc | 10 | $210 |
| Alcon | 3 | $134 |
| Thea Pharma Inc. | 6 | $111 |
| Alimera Sciences, Inc. | 6 | $106 |
| Harrow Eye, LLC | 4 | $93 |
| Spark Therapeutics, Inc. | 1 | $82 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $78 |
| Kala Pharmaceuticals, Inc. | 4 | $63 |
| Amgen | 3 | $57 |
| Aerie Pharmaceuticals, Inc. | 2 | $45 |
| Carl Zeiss Meditec USA, Inc. | 1 | $27 |
| Shire North American Group Inc | 1 | $23 |
| Sight Sciences, Inc. | 1 | $19 |
| Akorn, Inc. | 1 | $17 |
| Eyevance Pharmaceuticals LLC | 1 | $15 |
| Mallinckrodt Enterprises LLC | 1 | $15 |
| GSK | 1 | $15 |
| Travere Therapeutics, Inc. | 1 | $10 |
How this compares
$592,427 in reported general payments places this provider in the 90th percentile of 108 retina specialist providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other retina specialist in Houston
- Petros CarvounisHouston$40K
- Garvin DavisHouston$38K
- Sami DahrHouston$34K
- Ella LeungHouston$12K
- Keith BourgeoisHouston$7K
- Jaafar El AnnanHouston$6K
- Richard FishHouston$5K
- Lee TranHouston$4K
- Michael LamHouston$4K
- John AlappattHouston$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.